Ticker

No recent analyst price targets found for ENTX.

Latest News for ENTX

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced it will host a virtual Key Opinion Leader (KOL) webinar focused on the osteoporosis treatment landscape and the opportunity for its lead clinical candidate, EB613 (oral PTH (1-34) tablet), on Monday, April…

GlobeNewsWire • Apr 14, 2026
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has entered into a securities purchase agreement for a private placement (the “Private Placement”) led by funds affiliated with BVF Partners L.P. (“BVF”).

GlobeNewsWire • Apr 2, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for ENTX.

No House trades found for ENTX.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top